Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cohort C: Open-label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer

NCT06964165 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT06964165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06964165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cohort C: Open-label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer
Lead sponsor
Tesaro, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
April 14, 2022
Completion date
March 31, 2025
Enrollment
36 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms